Gujarat Kidney And Super Speciality Limited

Expensive valuation at PE 67.91 leaves limited room for earnings disappointment

Small operational base: standalone quarterly revenue ₹9–10 Cr with OPM volatility from 16.99% to 42.43% across recent quarters — verify cause and sustainability

Weak institutional participation (FII 4.88%, DII 0.56%) against promoter dominance (71.45%) — assess liquidity and public-market confidence

Typical healthcare sector exposure: regulatory changes, reimbursement pressure, staffing costs, and elective-procedure demand cycles

Consolidated revenue (₹34.29 Cr H1 FY2027) significantly exceeds standalone (₹9.24 Cr Q1 FY2027), suggesting acquisition or partnership strategy — verify pipeline

Minimal leverage (D/E 0.06) provides unfettered capacity to fund organic capex or inorganic expansion without equity dilution

Margin leadership: 32.85% OPM far exceeds typical hospital margins — verify if specialty mix, pricing power, or operational model is defensible at scale

ROE of 11.13% below cost of capital indicates reinvestment opportunity if growth investments boost returns